Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Daniel El Fassi; J. Paul Banga; Jacqueline A. Gilbert; Carolyn Padoa; Laszlo Hegedus; Claus H. Nielsen

doi:10.1016/j.clim.2008.09.007

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Daniel El Fassi, J. Paul Banga, Jacqueline A. Gilbert, Carolyn Padoa, Laszlo Hegedus, Claus H. Nielsen

Diabetes

Research output: Contribution to journal › Article › peer-review

74 Citations (Scopus)

Abstract

Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRab) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66 +/- 22%, upon treatment with rituximab and methimazole for 21 days (p

Original language	English
Pages (from-to)	252 - 258
Number of pages	7
Journal	CLINICAL IMMUNOLOGY
Volume	130
Issue number	3
DOIs	https://doi.org/10.1016/j.clim.2008.09.007
Publication status	Published - Mar 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clim.2008.09.007

Cite this

@article{bdc3fe79d83e4efabaa8feb212ae0842,

title = "Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies",

abstract = "Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRab) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66 +/- 22%, upon treatment with rituximab and methimazole for 21 days (p",

author = "{El Fassi}, Daniel and Banga, {J. Paul} and Gilbert, {Jacqueline A.} and Carolyn Padoa and Laszlo Hegedus and Nielsen, {Claus H.}",

year = "2009",

month = mar,

doi = "10.1016/j.clim.2008.09.007",

language = "English",

volume = "130",

pages = "252 -- 258",

journal = "CLINICAL IMMUNOLOGY",

publisher = "ACADEMIC PRESS INC",

number = "3",

}

TY - JOUR

T1 - Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

AU - El Fassi, Daniel

AU - Banga, J. Paul

AU - Gilbert, Jacqueline A.

AU - Padoa, Carolyn

AU - Hegedus, Laszlo

AU - Nielsen, Claus H.

PY - 2009/3

Y1 - 2009/3

N2 - Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRab) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66 +/- 22%, upon treatment with rituximab and methimazole for 21 days (p

AB - Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRab) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66 +/- 22%, upon treatment with rituximab and methimazole for 21 days (p

U2 - 10.1016/j.clim.2008.09.007

DO - 10.1016/j.clim.2008.09.007

M3 - Article

VL - 130

SP - 252

EP - 258

JO - CLINICAL IMMUNOLOGY

JF - CLINICAL IMMUNOLOGY

IS - 3

ER -

Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this